Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free Report) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for Corbus Pharmaceuticals in a report released on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings of ($1.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($5.89) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2027 earnings at ($1.52) EPS, Q3 2027 earnings at ($1.52) EPS and Q4 2027 earnings at ($1.52) EPS.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.54).
Other equities analysts also recently issued research reports about the company. Oppenheimer cut their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Wall Street Zen lowered Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $39.57.
Check Out Our Latest Stock Report on Corbus Pharmaceuticals
Corbus Pharmaceuticals Stock Performance
NASDAQ:CRBP opened at $3.93 on Wednesday. Corbus Pharmaceuticals has a 52 week low of $2.81 and a 52 week high of $12.88. The firm has a 50-day moving average price of $6.14 and a two-hundred day moving average price of $8.43. The firm has a market cap of $73.38 million, a price-to-earnings ratio of -0.63 and a beta of 2.80.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of CRBP. Orbimed Advisors LLC grew its position in shares of Corbus Pharmaceuticals by 8.8% during the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company’s stock valued at $16,313,000 after acquiring an additional 140,000 shares during the period. Exome Asset Management LLC raised its holdings in shares of Corbus Pharmaceuticals by 67.8% in the 1st quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company’s stock worth $2,199,000 after purchasing an additional 94,593 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Corbus Pharmaceuticals by 76.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock worth $1,281,000 after purchasing an additional 59,248 shares during the period. Seven Fleet Capital Management LP raised its holdings in shares of Corbus Pharmaceuticals by 51.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after purchasing an additional 28,937 shares during the period. Finally, Doliver Advisors LP purchased a new position in Corbus Pharmaceuticals in the third quarter valued at approximately $518,000. 64.64% of the stock is owned by institutional investors.
Insider Transactions at Corbus Pharmaceuticals
In related news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $4.10, for a total transaction of $1,742,500.00. Following the completion of the sale, the insider owned 1,919,971 shares in the company, valued at approximately $7,871,881.10. This trade represents a 18.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 3.50% of the company’s stock.
Key Headlines Impacting Corbus Pharmaceuticals
Here are the key news stories impacting Corbus Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target. The analyst expects losses of $1.58 per share in Q1 2027 and $1.52 per share in each of Q2–Q4. The rating and target may provide support, though the estimates still indicate continued losses.
- Negative Sentiment: Corbus reported a Q3 2026 loss of $1.81 per share, missing the consensus estimate of a $1.27 loss by $0.54. The earnings shortfall could pressure the stock. Corbus Q3 2026 press release
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.
Featured Articles
- Five stocks we like better than Corbus Pharmaceuticals
- The Trade Desk Beats on Revenue, But the Fine Print Matters
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
